Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol. 2018;62:29–39.

Article  CAS  PubMed  Google Scholar 

Wright JJ, Powers AC, Johnson DB. Endocrine toxicities of immune checkpoint inhibitors. Nat Rev Endocrinol. 2021;17:389–99.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu J, Zhou H, Zhang Y, Fang W, Yang Y, Huang Y, et al. Reporting of immune checkpoint inhibitor therapy-associated diabetes, 2015–2019. Diabetes Care. 2020;43:e79–80.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tachibana M, Imagawa A. Type 1 diabetes related to immune checkpoint inhibitors. Best Pract Res Clin Endocrinol Metab. 2022;36:101657.

Article  CAS  PubMed  Google Scholar 

Kawasaki E. Anti-islet autoantibodies in type 1 diabetes. Int J Mol Sci. 2023;24:10012.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baden MY, Imagawa A, Abiru N, Awata T, Ikegami H, Uchigata Y, et al. Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell death-1 therapy. Diabetol Int. 2019;10:58–66.

Article  PubMed  Google Scholar 

Clotman K, Janssens K, Specenier P, Weets I, De Block CEM. Programmed cell death-1 inhibitor-induced Type 1 diabetes mellitus. J Clin Endocrinol Metab. 2018;103:3144–54.

Article  PubMed  Google Scholar 

Imagawa A, Hanafusa T, Awata T, Ikegami H, Uchigata Y, Osawa H, et al. Report of the committee of the Japan diabetes society on the research of fulminant and acute-onset type 1 diabetes mellitus: new diagnostic criteria of fulminant type 1 diabetes mellitus (2012). J Diabetes Investig. 2012;3:536–9.

Article  PubMed  PubMed Central  Google Scholar 

Kawabata Y, Ikegami H, Kawaguchi Y, Fujisawa T, Shintani M, Ono M, et al. Asian-specific HLA haplotypes reveal heterogeneity of the contribution of HLA-DR and -DQ haplotypes to susceptibility to type 1 diabetes. Diabetes. 2002;51:545–51.

Article  CAS  PubMed  Google Scholar 

Shiba M, Inaba H, Ariyasu H, Kawai S, Inagaki Y, Matsuno S, et al. Fulminant type 1 diabetes mellitus accompanied by positive conversion of anti-insulin antibody after the administration of anti-CTLA-4 antibody following the discontinuation of anti-PD-1 antibody. Intern Med. 2018;57:2029–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lowe JR, Perry DJ, Salama AKS, Mathews CE, Moss LG, Hanks BA. Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy. J Immunother Cancer. 2016;4:89.

Article  PubMed  PubMed Central  Google Scholar 

Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, et al. Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes. 2018;67:1471–80.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lernmark Å. Etiology of autoimmune islet disease: timing is everything. Diabetes. 2021;70:1431–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kawasaki E, Nakamura K, Kuriya G, Satoh T, Kobayashi M, Kuwahara H, et al. Differences in the humoral autoreactivity to zinc transporter 8 between childhood- and adult-onset type 1 diabetes in Japanese patients. Clin Immunol. 2011;138:146–53.

Article  CAS  PubMed  Google Scholar 

Towns R, Pietropaolo M. GAD65 autoantibodies and its role as biomarker of type 1 diabetes and Latent Autoimmune Diabetes in Adults (LADA). Drugs Future. 2011;36:847.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Imagawa A, Hanafusa T, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, et al. Fulminant type 1 diabetes: a nationwide survey in Japan. Diabetes Care. 2003;26:2345–52.

Article  PubMed  Google Scholar 

Tsutsumi C, Imagawa A, Ikegami H, Makino H, Kobayashi T, Hanafusa T, et al. Class II HLA genotype in fulminant type 1 diabetes: a nationwide survey with reference to glutamic acid decarboxylase antibodies. J Diabetes Investig. 2012;3:62–9.

Article  CAS  PubMed  Google Scholar 

Wu L, Tsang V, Menzies AM, Sasson SC, Carlino MS, Brown DA, et al. Risk factors and characteristics of checkpoint inhibitor-associated autoimmune diabetes mellitus (CIADM): a systematic review and delineation from type 1 diabetes. Diabetes Care. 2023;46:1292–9.

Article  CAS  PubMed  Google Scholar 

Siljander HT, Veijola R, Reunanen A, Virtanen SM, Akerblom HK, Knip M. Prediction of type 1 diabetes among siblings of affected children and in the general population. Diabetologia. 2007;50:2272–5.

Article  CAS  PubMed  Google Scholar 

Insel RA, Dunne JL, Atkinson MA, Chiang JL, Dabelea D, Gottlieb PA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015;38:1964–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yokota I, Matsuda J, Naito E, Ito M, Shima K, Kuroda Y. Comparison of GAD and ICA512/IA-2 antibodies at and after the onset of IDDM. Diabetes Care. 1998;21:49–52.

Article  CAS  PubMed  Google Scholar 

Kawata S, Kozawa J, Yoneda S, Fujita Y, Kashiwagi-Takayama R, Kimura T, et al. Inflammatory cell infiltration into islets without PD-L1 expression is associated with the development of immune checkpoint inhibitor-related Type 1 diabetes in genetically susceptible patients. Diabetes. 2023;72:511–9.

Article  CAS  PubMed  PubMed Central  Google Scholar